[Chronic use of proton pump inhibitors: is the risk of osteoporosis and fractures real?]

Gastroenterol Hepatol. 2011 Apr;34(4):271-7. doi: 10.1016/j.gastrohep.2011.01.002. Epub 2011 Mar 17.
[Article in Spanish]

Abstract

Proton pump inhibitors (PPI) are one of the most widely used groups of drugs and their potential toxicity is periodically reviewed, emphasizing aspects originally considered secondary. The present review analyzes the physiological and pharmacological bases and the scarce clinical evidence for a potential association between the continued administration of PPI and the development of osteoporosis and bone fractures. Both disorders are clearly related to calcium homeostasis and are highly important in elderly patients due to their poor general prognosis and disabling consequences.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Achlorhydria / chemically induced
  • Achlorhydria / physiopathology
  • Aging / metabolism
  • Calcium / metabolism
  • Calcium, Dietary / pharmacokinetics
  • Comorbidity
  • Disease Susceptibility
  • Fractures, Spontaneous / chemically induced*
  • Fractures, Spontaneous / etiology
  • Gastric Acid / metabolism
  • Gastrins / metabolism
  • Homeostasis
  • Humans
  • Hyperparathyroidism, Secondary / chemically induced
  • Intestinal Absorption / drug effects
  • Malabsorption Syndromes / chemically induced
  • Malabsorption Syndromes / physiopathology
  • Models, Biological
  • Osteoporosis / chemically induced*
  • Osteoporosis / etiology
  • Osteoporosis / physiopathology
  • Proton Pump Inhibitors / adverse effects*
  • Proton Pump Inhibitors / therapeutic use
  • Risk

Substances

  • Calcium, Dietary
  • Gastrins
  • Proton Pump Inhibitors
  • Calcium